TDC
ANIK icon

Thompson Davis & Co’s Anika Therapeutics ANIK Stock Holding History

Thompson Davis & Co’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-400
Closed -$22K – 621
2017
Q4 		$22K Sell
400
-150
-27% -$8.3K 0.05% 306
2017
Q3 		$32K Buy
+550
New +$28.8K 0.06% 335
2017
Q2 		– Sell
-325
Closed -$14K – 1068
2017
Q1 		$14K Buy
+325
New +$15.5K 0.02% 602

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

Thompson Davis & Co's ANIK Position: Q1 2018 in Review

Thompson Davis & Co sold out of Anika Therapeutics (ANIK) in Q1 2018, closing a stake of 400 shares — an estimated $22K sold.

Thompson Davis & Co first reported a position in ANIK in Q1 2017 and held it in 3 quarters. The position peaked at $32K in Q3 2017. 170 funds tracked by Wall St. Rank hold ANIK as of Q1 2018.

  • Thompson Davis & Co reported no remaining Anika Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Thompson Davis & Co sold 400 Anika Therapeutics shares in Q1 2018, an estimated $22K.
  • Thompson Davis & Co first reported a position in Anika Therapeutics in Q1 2017 and held it in 3 quarters.
  • Thompson Davis & Co's Anika Therapeutics position peaked at $32K in Q3 2017.
  • 170 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2018.

Based on Thompson Davis & Co's 13F filing for Q1 2018, filed 2 May 2018.